FDA: Long-Term Plavix Use Doesn’t Increase Death Risk

(November 9, 2015, 1:47 PM EST) -- SILVER SPRING, Md. — Long-term use of the anticoagulant drug Plavix (clopidogrel) does not increase or decrease the overall risk of death in patients with or at risk for heart disease, the Food and Drug Administration announced Nov. 6 in a drug safety communication.

The FDA said its evaluation of the dual antiplatelet therapy clinical trials and other trials “also does not suggest that clopidogrel increases the risk of cancer or death from cancer.”

“The results indicate that long-term (12 months or longer) dual antiplatelet therapy...
To view the full article, register now.